Aug 18, 2025 • Benzinga
NEUTRAL
What's Going On With Tonix Pharma Stock Monday? - Tonix Pharmaceuticals ( NASDAQ:TNXP )
Tonmya reduced daily pain scores in Phase 3 trials of nearly 1,000 patients. Tonix ended June with $125.3 million cash, funding operations into Q3 2026. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.
Aug 05, 2025 • Benzinga
SOMEWHAT-BULLISH
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - Axsome Therapeutics ( NASDAQ:AXSM )
Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday. Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share.
Aug 05, 2025 • Zacks Commentary
NEUTRAL
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Aug 04, 2025 • Zacks Commentary
NEUTRAL
Axsome Therapeutics ( AXSM ) Reports Q2 Loss, Beats Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 04, 2025 • Motley Fool
NEUTRAL
Axsome ( AXSM ) Q2 Revenue Soars 72%
Axsome Therapeutics ( NASDAQ:AXSM ) , a biopharmaceutical company focused on central nervous system ( CNS ) disorders, released its earnings on August 4, 2025. The company reported GAAP revenue of $150.0 million, up 72% compared to the prior year period, and a net loss per share of $ ( 0.97 ) ( ...
Jul 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Amgen ( AMGN ) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.